2 results
Approved WMOCompleted
To demonstrate non-inferiority of a T2T strategy in which conventional synthetic disease modifying drugs (csDMARDs) refractory RApatients are initially treated with tsDMARD baricitinib versus the comparable T2T strategy in which patients are…
Approved WMOCompleted
Primary:Compare the efficacy of single IV injection with otilimab 90 mg in adults with severe pulmonary COVID-19 related disease.Secondary:Other aspects of efficacy. Safety and tolerability.